MyMD Pharma Up 9% On Topline Phase 2 Results For Oral TNF-a Inhibitor MYMD-1
Shares of MyMD Pharmaceuticals, Inc. (MYMD) are up 9% on Monday after the company reported that it achieved its primary and secondary endpoints from its randomized Phase 2 study of oral TNF-a inhibitor, MYMD-1 in patients with chronic inflammation associated with sarcopenia, or age-related frailty.
Source: rttnews.com